Srihari Veeraraghavan
Overview
Dr. Srihari Veeraraghavan completed his medical education in India at the University of Madras, obtaining his MD in 1992. He trained in Internal Medicine at the State university of New York at Brooklyn from 1993-1996. He then moved to the University of Southern California in Los Angeles for fellowship training in Pulmonary & Critical Care Medicine from 1996-1999. He subsequently went to London, England where he worked at the Royal Brompton hospital. Here under the tutelage of Prof Roland du Bois he spent three years specializing in interstitial lung diseases. Dr. Veeraraghavan joined Emory University in 2010 after spending some time in India and in California practicing pulmonary and critical care medicine.
He is currently the director of the interstitial lung disease program at Emory. His clinic also serves as a regional referral center for several rare lung diseases. He is actively involved in research conducting several clinical trials. In addition to seeing patients in the inpatient and out patient settings he is involved in training residents and fellows in pulmonary medicine.
Academic Appointment
- Associate Professor, Division of Pulmonary and Critical Care Medicine, Emory University school of Medicine
Education
Degrees
- M.B. from University of Madras
- B.S from M.B.
Research
Publications
-
Thoracic and Cardiovascular Imaging Manifestations of Lupus.
Radiographics Volume: 45 Page(s): e240114
01/01/2025 Authors: Gomez CJ; Naeem M; Bechel MA; Battle W; Amin S; Hamid A; Berkowitz E; Veeraraghavan S; Filev P -
Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis.
BMC Pulm Med Volume: 24 Page(s): 468
09/27/2024 Authors: Lobo LJ; Liu Y; Li P; Ramaswamy M; Swaminathan AC; Veeraraghavan S; Fan Y; Neely ML; Palmer SM; Olson AL -
Pulmonary hypertension mortality trends in United States 1999-2019.
Ann Epidemiol Volume: 75 Page(s): 47 - 52
11/01/2022 Authors: Kang M; Hart CM; Kempker JA; Veeraraghavan S; Trammell AW -
An updated approach to determine minimal clinically important differences in idiopathic pulmonary fibrosis.
ERJ Open Res Volume: 7
10/01/2021 Authors: Kang M; Veeraraghavan S; Martin GS; Kempker JA -
CT Morphologic Characteristics and Variant Patterns of Interstitial Pulmonary Fibrosis in Systemic Lupus Erythematosus.
Radiol Cardiothorac Imaging Volume: 3 Page(s): e200625
08/01/2021 Authors: Brady D; Berkowitz EA; Sharma A; Ackman JB; Bernheim A; Chung M; Veeraraghavan S; Little BP -
Minimal clinically important difference in idiopathic pulmonary fibrosis.
Breathe (Sheff) Volume: 17 Page(s): 200345
06/01/2021 Authors: Kang M; Marts L; Kempker JA; Veeraraghavan S -
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Imaging and Clinical Features of a Frequently Delayed Diagnosis.
AJR Am J Roentgenol Volume: 215 Page(s): 1312 - 1320
12/01/2020 Authors: Little BP; Junn JC; Zheng KS; Sanchez FW; Henry TS; Veeraraghavan S; Berkowitz EA -
LAM MIMICS: AIRWAY-CENTERED CYSTIC LUNG DISEASE
Volume: 158 Page(s): 1056A - 1056A
10/01/2020 Authors: Gripaldo R; Berkowitz E; Schneider F; Sica G; Veeraraghavan S -
36 Item Short Form Survey Health Transition Question and Changes in Various Physiologic and Patient Related Outcome Measures in Patients with Idiopathic Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine Volume: 201 Page(s): A3382 - A3382
05/01/2020 Authors: Kang M; Veeraraghavan S; Martin GS; Kempker J -
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Lancet Respir Med Volume: 8 Page(s): 453 - 460
05/01/2020 Authors: Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S